AR063317A1 - Formulacion secada por aspersion - Google Patents

Formulacion secada por aspersion

Info

Publication number
AR063317A1
AR063317A1 ARP070104580A ARP070104580A AR063317A1 AR 063317 A1 AR063317 A1 AR 063317A1 AR P070104580 A ARP070104580 A AR P070104580A AR P070104580 A ARP070104580 A AR P070104580A AR 063317 A1 AR063317 A1 AR 063317A1
Authority
AR
Argentina
Prior art keywords
drug
solid dispersion
dispersion
dihydro
benzyl
Prior art date
Application number
ARP070104580A
Other languages
English (en)
Inventor
Douglas Alan Lorenza
David Keith Lyon
Rodney James Ketner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR063317A1 publication Critical patent/AR063317A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen composiciones farmacéuticas que comprenden un fármaco ionizable poco soluble en agua, una especie cationica y un polímero de dispersion, junto con un proceso para formar las composiciones. La forma neutra del fármaco tiene (i) una solubilidad menor de 1 mg/ml en solucion acuosa a un valor de pH comprendido entre 6 y 7, (ii) una solubilidad menor de 20 mg/ml en un disolvente orgánico volátil, y (iii) un valor de pKa ácido mayor de 5, estando al menos 90% en peso del fármaco en la dispersion solida en una forma no cristalina. El fármaco, la especie cationica y el polímero de dispersion constituyen al menos 80% en peso de la dispersion solida. Reivindicacion 11: La dispersion solida de cualquiera de las reivindicaciones anteriores, caracterizada porque dicho fármaco es ciclopropilmetil-amida del ácido 6-amino-9-bencil-8-oxo-8,9-dihidro-7H-purina-2-carboxílico. Reivindicacion 12: La dispersion solida de cualquiera de las reivindicaciones anteriores, caracterizada porque dicho fármaco es 4-amino-1-bencil-6-trifluorometil-1,3-dihidro-imidazo[4,5-c]piridina-2-ona. Reivindicacion 13: La dispersion solida de cualquiera de las reivindicaciones anteriores, caracterizada porque dicho fármaco es 6-(5-cloro-3-metil- benzofuran-2-sulfonil)-2H-piridazin-3-ona.
ARP070104580A 2006-10-17 2007-10-16 Formulacion secada por aspersion AR063317A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82972006P 2006-10-17 2006-10-17

Publications (1)

Publication Number Publication Date
AR063317A1 true AR063317A1 (es) 2009-01-21

Family

ID=39048880

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104580A AR063317A1 (es) 2006-10-17 2007-10-16 Formulacion secada por aspersion

Country Status (8)

Country Link
US (1) US8372836B2 (es)
EP (1) EP2101741B1 (es)
JP (1) JP2008100997A (es)
AR (1) AR063317A1 (es)
AT (1) ATE476966T1 (es)
DE (1) DE602007008470D1 (es)
TW (1) TW200819148A (es)
WO (1) WO2008047201A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8535716B2 (en) 2004-04-01 2013-09-17 Tsrl, Inc. Methods and composition of extended delivery of water insoluble drugs
EP1888587A1 (en) * 2005-05-04 2008-02-20 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20110312916A1 (en) 2009-02-05 2011-12-22 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
US20120076838A1 (en) 2009-05-27 2012-03-29 Samyang Biopharmaceuticals Corporation Poorly soluble drug containing microsphere with improved bioavailabilty and method of preparing the same
CN103037843A (zh) * 2010-06-23 2013-04-10 麦它波莱克斯股份有限公司 5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
US9757465B2 (en) 2012-04-11 2017-09-12 Dow Global Technologies Llc Composition comprising an organic diluent and a cellulose ether
US10525010B2 (en) 2012-05-02 2020-01-07 Capsugel Belgium Nv Aqueous dispersions of controlled release polymers and shells and capsules thereof
JP6235584B2 (ja) 2012-07-17 2017-11-22 ダウ グローバル テクノロジーズ エルエルシー 高置換ヒドロキシアルキルメチルセルロースを含む固体分散体
BR112014031471B1 (pt) 2012-07-17 2020-12-01 Dow Global Technologies Llc composição líquida, uso da composição líquida, dispersão sólida, processo para produzir a dispersão sólida e processo para revestir uma forma de dosagem
US9737538B2 (en) 2013-02-12 2017-08-22 Bend Research, Inc. Solid dispersions of low-water solubility actives
EP2956121B1 (en) * 2013-02-12 2018-05-30 Bend Research, Inc. Solid dispersions of low-water solubility actives
US9884067B2 (en) 2013-03-14 2018-02-06 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
JP6353061B2 (ja) 2013-09-25 2018-07-04 ダウ グローバル テクノロジーズ エルエルシー 有機液体希釈剤及び特定のヒドロキシアルキルメチルセルロースを含む組成物
JP2016540017A (ja) 2013-12-11 2016-12-22 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激物質
EP3082803A4 (en) * 2013-12-20 2017-05-31 Phosphorex Inc. Indirubin solid dispersion composition
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2015174475A1 (ja) * 2014-05-15 2015-11-19 株式会社セラバリューズ 経口摂取用組成物
CN106456555B (zh) * 2014-05-20 2019-05-07 陶氏环球技术有限责任公司 包含酯化纤维素醚的胶囊壳
DE202014010561U1 (de) * 2014-08-13 2016-01-04 Clariant International Ltd. VOC-arme Amine als oberflächenaktiver Bestandteil in Dispersionen
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
WO2016087665A2 (en) * 2014-12-05 2016-06-09 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating cystic fibrosis
CN107530338B (zh) 2015-04-21 2020-12-01 艾格尔峰生物制药有限公司 包含洛那法尼和利托那韦的药物组合物
US20180250232A1 (en) * 2015-09-03 2018-09-06 Merck Sharp & Dohme Corp. Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations
JP6971043B2 (ja) 2016-03-04 2021-11-24 株式会社リコー 微粒子の製造方法
MX2018012557A (es) 2016-04-15 2019-07-04 Janssen Sciences Ireland Uc Combinaciones y métodos que comprenden un inhibidor del ensamblaje de la cápside.
JP2020524718A (ja) * 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの複素環式小分子調節因子
CR20200378A (es) 2018-03-14 2021-01-08 Janssen Sciences Ireland Unlimited Co Régimen posológico del modulador del emsalblaje de la cápside
US11708463B2 (en) 2018-04-06 2023-07-25 Capsugel Belgium Nv Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
MX2021001063A (es) * 2018-07-30 2021-04-12 Chugai Pharmaceutical Co Ltd Dispersion solida de derivado de hidantoina.
JP2022544406A (ja) * 2019-08-15 2022-10-18 キャプシュゲル・ベルジウム・エヌ・ヴィ 噴霧された固体分散体の処理助剤としてのアンモニア

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE400252T1 (de) * 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
DE60233874D1 (de) * 2001-06-22 2009-11-12 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
TNSN03137A1 (en) * 2001-06-22 2005-12-23 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS COMPRISING LOW SOLUBILITY AND / OR ACID SENSITIVE DRUGS AND NEUTRALIZED ACID POLYMERS.
WO2004056358A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US8617604B2 (en) * 2005-02-03 2013-12-31 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
EP1888587A1 (en) * 2005-05-04 2008-02-20 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
EP1893178A1 (en) * 2005-05-31 2008-03-05 Pfizer Products Incorporated PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS
ES2374455T3 (es) * 2006-02-17 2012-02-16 Pfizer Limited Derivados de 3-deazapurinza como moduladores de tlr7.

Also Published As

Publication number Publication date
US20100029667A1 (en) 2010-02-04
EP2101741A2 (en) 2009-09-23
WO2008047201A2 (en) 2008-04-24
US8372836B2 (en) 2013-02-12
JP2008100997A (ja) 2008-05-01
DE602007008470D1 (en) 2010-09-23
TW200819148A (en) 2008-05-01
ATE476966T1 (de) 2010-08-15
EP2101741B1 (en) 2010-08-11
WO2008047201A3 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
AR063317A1 (es) Formulacion secada por aspersion
ES2561108T3 (es) Composiciones inyectables para la liberación controlada de compuesto farmacológicamente activo
WO2011018635A3 (en) Photosensitizing compositions
BR112018008880A8 (pt) composto 7-(tiazol-5-il) pirrolopirimidina como agonista de tlr7
DOP2020000062A (es) Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para el uso como principio activo farmacéutico
WO2007084460A8 (en) Pharmaceutical compositions with enhanced stability
CR20110312A (es) Compuestos orgánicos
MX2010004222A (es) Formulaciones solidas de compuestos cristalinos.
GT200800219A (es) Derivados de purina para utilizarse como agonistas del receptor de adenosina a2a
NO20056239L (no) Hyaluronsyre nanopartikler
CR10404A (es) Composicion farmaceutica de liberacion sostenida sobre la base de un sistema de liberacion que comprende un polimero acido-soluble y un polimero ph-dependiente
PE20080170A1 (es) Proceso de secado por rociado de un farmaco
PE20200404A1 (es) Composicion farmaceutica de clorhidrato de s-ketamina
PE20150732A1 (es) Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso
BRPI0620063B8 (pt) composição farmacêutica de liberação sustentada na forma de micropartículas, uso, e kit de administração
NI201000145A (es) DERIVADOS DE IMIDAZO - [1, 2-b] - PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET.
ATE376423T1 (de) Gelierende wässrige pharmazeutische zusammensetzungen
BRPI0921705B8 (pt) composição farmacêutica antimicrobiana e seu uso
CO6190545A2 (es) Metodo de preparacion de microcapsulas de liberacion sostenida que tiene buena propiedad que inhibe el quebramiento inicial y de esta manera las microcapsulas
WO2010045281A3 (en) Stable aqueous formulations of water insoluble or poorly soluble drugs
WO2010151644A3 (en) Antineoplastic hydrogels, and enzyme-instructed preparations thereof
AR082049A1 (es) Formulaciones liquidas de rupatadina fumarato
BR112014016472A8 (pt) formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
ES2895772T1 (es) Solución de bortezomib lista para usar

Legal Events

Date Code Title Description
FA Abandonment or withdrawal